메뉴 건너뛰기




Volumn 4, Issue 12, 2014, Pages

Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): Protocol for a double-blind, randomised, placebo-controlled, multicentre trial

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; BILIRUBIN; BIOCHEMICAL MARKER; C REACTIVE PROTEIN; CALGRANULIN; CREATININE; HEMOGLOBIN; INFLIXIMAB; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR;

EID: 84920519308     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-005887     Document Type: Article
Times cited : (10)

References (38)
  • 1
    • 79953805710 scopus 로고    scopus 로고
    • An evidence-based systematic review on medical therapies for inflammatory bowel disease
    • quiz S26
    • Talley NJ, Abreu MT, Achkar JP, et al. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol 2011;106(Suppl 1):S2 -25; quiz S26.
    • (2011) Am J Gastroenterol , vol.106 , pp. S2-S25
    • Talley, N.J.1    Abreu, M.T.2    Achkar, J.P.3
  • 2
    • 34447102570 scopus 로고    scopus 로고
    • American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006
    • Clark M, Colombel JF, Feagan BC, et al. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology 2007;133:312-39.
    • (2007) Gastroenterology , vol.133 , pp. 312-339
    • Clark, M.1    Colombel, J.F.2    Feagan, B.C.3
  • 3
    • 75149161836 scopus 로고    scopus 로고
    • The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management
    • Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010;4:28-62.
    • (2010) J Crohns Colitis , vol.4 , pp. 28-62
    • Dignass, A.1    Van Assche, G.2    Lindsay, J.O.3
  • 4
    • 38749095183 scopus 로고    scopus 로고
    • European evidence-based consensus on the management of ulcerative colitis: Current management
    • Travis SP, Stange EF, Lémann M, et al. European evidence-based consensus on the management of ulcerative colitis: current management. J Crohns Colitis 2008;2:24-62.
    • (2008) J Crohns Colitis , vol.2 , pp. 24-62
    • Travis, S.P.1    Stange, E.F.2    Lémann, M.3
  • 5
    • 79751472562 scopus 로고    scopus 로고
    • The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: When to start, when to stop, which drug to choose, and how to predict response?
    • quiz 213
    • D'Haens GR, Panaccione R, Higgins PDR, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 2011;106:199-212; quiz 213.
    • (2011) Am J Gastroenterol , vol.106 , pp. 199-212
    • D'Haens, G.R.1    Panaccione, R.2    Higgins, P.D.R.3
  • 6
    • 77950843556 scopus 로고    scopus 로고
    • Anti-TNF and Crohn's disease: When should we stop?
    • Louis E, Belaiche J, Reenaers C. Anti-TNF and Crohn's disease: when should we stop? Curr Drug Targets 2010;11:148-51.
    • (2010) Curr Drug Targets , vol.11 , pp. 148-151
    • Louis, E.1    Belaiche, J.2    Reenaers, C.3
  • 7
    • 79952795096 scopus 로고    scopus 로고
    • Review article: IFX for Crohn's disease treatment - Shifting therapeutic strategies after 10 years of clinical experience
    • Danese S, Colombel JF, Reinisch W, et al. Review article: IFX for Crohn's disease treatment - shifting therapeutic strategies after 10 years of clinical experience. Aliment Pharmacol Ther 2011;33:857-69.
    • (2011) Aliment Pharmacol Ther , vol.33 , pp. 857-869
    • Danese, S.1    Colombel, J.F.2    Reinisch, W.3
  • 8
    • 83555174451 scopus 로고    scopus 로고
    • Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission
    • Clarke K, Regueiro M. Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission. Inflamm Bowel Dis 2012;18:174-9.
    • (2012) Inflamm Bowel Dis , vol.18 , pp. 174-179
    • Clarke, K.1    Regueiro, M.2
  • 9
    • 79958095982 scopus 로고    scopus 로고
    • Severe infusion reactions to IFX: Aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease
    • Steenholdt C, Svenson M, Bendtzen K, et al. Severe infusion reactions to IFX: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011;34:51-8.
    • (2011) Aliment Pharmacol Ther , vol.34 , pp. 51-58
    • Steenholdt, C.1    Svenson, M.2    Bendtzen, K.3
  • 10
    • 79959929224 scopus 로고    scopus 로고
    • Incidence of acute severe infusion reactions to IFX depends on definition used rather than assay: Authors' reply
    • Steenholdt C, Svenson M, Bendtzen K, et al. Incidence of acute severe infusion reactions to IFX depends on definition used rather than assay: authors' reply. Aliment Pharmacol Ther 2011;34:404-5.
    • (2011) Aliment Pharmacol Ther , vol.34 , pp. 404-405
    • Steenholdt, C.1    Svenson, M.2    Bendtzen, K.3
  • 11
    • 79953761841 scopus 로고    scopus 로고
    • Guidelines for the management of inflammatory bowel disease in adults
    • Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011;60:571-607.
    • (2011) Gut , vol.60 , pp. 571-607
    • Mowat, C.1    Cole, A.2    Windsor, A.3
  • 12
    • 83955162272 scopus 로고    scopus 로고
    • Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after IFX therapy is stopped
    • quiz e31
    • Louis E, Mary JY, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after IFX therapy is stopped. Gastroenterology 2012;142:63-70.e5; quiz e31.
    • (2012) Gastroenterology , vol.142 , pp. 63-70.e5
    • Louis, E.1    Mary, J.Y.2    Vernier-Massouille, G.3
  • 13
    • 84872689289 scopus 로고    scopus 로고
    • Predictors of relapse in patients with Crohn's disease in remission after 1 year of biological therapy
    • Molnár T, Lakatos PL, Farkas K, et al. Predictors of relapse in patients with Crohn's disease in remission after 1 year of biological therapy. Aliment Pharmacol Ther 2013;37:225-33.
    • (2013) Aliment Pharmacol Ther , vol.37 , pp. 225-233
    • Molnár, T.1    Lakatos, P.L.2    Farkas, K.3
  • 14
    • 84859590148 scopus 로고    scopus 로고
    • Outcome after discontinuation of IFX in patients with inflammatory bowel disease in clinical remission: An observational Danish single center study
    • Steenholdt C, Molazahi A, Ainsworth MA, et al. Outcome after discontinuation of IFX in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study. Scand J Gastroenterol 2012;47:518-27.
    • (2012) Scand J Gastroenterol , vol.47 , pp. 518-527
    • Steenholdt, C.1    Molazahi, A.2    Ainsworth, M.A.3
  • 15
    • 36549071038 scopus 로고    scopus 로고
    • Clinical course in Crohn's disease: Results of a Norwegian population-based ten-year follow-up study
    • Solberg IC, Vatn MH, Høie O, et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol 2007;5:1430-8.
    • (2007) Clin Gastroenterol Hepatol , vol.5 , pp. 1430-1438
    • Solberg, I.C.1    Vatn, M.H.2    Høie, O.3
  • 16
    • 0037434552 scopus 로고    scopus 로고
    • Influence of immunogenicity on the long-term efficacy of IFX in Crohn's disease
    • Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of IFX in Crohn's disease. N Engl J Med 2003;348:601-8.
    • (2003) N Engl J Med , vol.348 , pp. 601-608
    • Baert, F.1    Noman, M.2    Vermeire, S.3
  • 18
    • 62049083383 scopus 로고    scopus 로고
    • Loss of response and requirement of IFX dose intensification in Crohn's disease: A review
    • Gisbert JP, Panés J. Loss of response and requirement of IFX dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009;104:760-7.
    • (2009) Am J Gastroenterol , vol.104 , pp. 760-767
    • Gisbert, J.P.1    Panés, J.2
  • 19
    • 79751477764 scopus 로고    scopus 로고
    • Cut-off levels and diagnostic accuracy of IFX trough levels and anti-IFX antibodies in Crohn's disease
    • Steenholdt C, Bendtzen K, Brynskov J, et al. Cut-off levels and diagnostic accuracy of IFX trough levels and anti-IFX antibodies in Crohn's disease. Scand J Gastroenterol 2011;46:310-18.
    • (2011) Scand J Gastroenterol , vol.46 , pp. 310-318
    • Steenholdt, C.1    Bendtzen, K.2    Brynskov, J.3
  • 20
    • 70350645060 scopus 로고    scopus 로고
    • Individual medicine in inflammatory bowel disease: Monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies
    • Bendtzen K, Ainsworth M, Steenholdt C, et al. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. Scand J Gastroenterol 2009;44:774-81.
    • (2009) Scand J Gastroenterol , vol.44 , pp. 774-781
    • Bendtzen, K.1    Ainsworth, M.2    Steenholdt, C.3
  • 22
    • 84864655177 scopus 로고    scopus 로고
    • Clinical implications of variations in anti-IFX antibody levels in patients with inflammatory bowel disease
    • Steenholdt C, Al-Khalaf M, Brynskov J, et al. Clinical implications of variations in anti-IFX antibody levels in patients with inflammatory bowel disease. Inflamm Bowel Dis 2012;18:2209-17.
    • (2012) Inflamm Bowel Dis , vol.18 , pp. 2209-2217
    • Steenholdt, C.1    Al-Khalaf, M.2    Brynskov, J.3
  • 23
    • 0026748231 scopus 로고
    • Incidence and prevalence of Crohn's disease in the county of Copenhagen, 1962-87: A sixfold increase in incidence
    • Munkholm P, Langholz E, Nielsen OH, et al. Incidence and prevalence of Crohn's disease in the county of Copenhagen, 1962-87: a sixfold increase in incidence. Scand J Gastroenterol 1992;27:609-14.
    • (1992) Scand J Gastroenterol , vol.27 , pp. 609-614
    • Munkholm, P.1    Langholz, E.2    Nielsen, O.H.3
  • 24
    • 78649583974 scopus 로고    scopus 로고
    • Endoscopic evaluation of Crohn's disease activity: Comparison of the CDEIS and the SES-CD
    • Internet
    • Sipponen T, Nuutinen H, Turunen U, et al. Endoscopic evaluation of Crohn's disease activity: Comparison of the CDEIS and the SES-CD [Internet]. Inflamm Bowel Dis 2010;16:2131-6.
    • (2010) Inflamm Bowel Dis , vol.16 , pp. 2131-2136
    • Sipponen, T.1    Nuutinen, H.2    Turunen, U.3
  • 25
    • 4744375545 scopus 로고    scopus 로고
    • Development and validation of a new, simplified endoscopic activity score for Crohn's disease: The SES-CD
    • Daperno M, D'Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 2004;60:505-12.
    • (2004) Gastrointest Endosc , vol.60 , pp. 505-512
    • Daperno, M.1    D'Haens, G.2    Van Assche, G.3
  • 26
    • 84862815614 scopus 로고    scopus 로고
    • MR enterography correlates highly with colonoscopy and histology for both distal ileal and colonic Crohn's disease in 310 patients
    • Grand DJ, Kampalath V, Harris A, et al. MR enterography correlates highly with colonoscopy and histology for both distal ileal and colonic Crohn's disease in 310 patients. Eur J Radiol 2012;81:e763-9.
    • (2012) Eur J Radiol , vol.81 , pp. e763-e769
    • Grand, D.J.1    Kampalath, V.2    Harris, A.3
  • 27
    • 77950116998 scopus 로고    scopus 로고
    • MR enterographic manifestations of small bowel Crohn disease
    • Tolan DJ, Greenhalgh R, Zealley IA, et al. MR enterographic manifestations of small bowel Crohn disease. Radiographics 2010;30:367-84.
    • (2010) Radiographics , vol.30 , pp. 367-384
    • Tolan, D.J.1    Greenhalgh, R.2    Zealley, I.A.3
  • 28
    • 0017227303 scopus 로고
    • Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study
    • Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976;70:439-44.
    • (1976) Gastroenterology , vol.70 , pp. 439-444
    • Best, W.R.1    Becktel, J.M.2    Singleton, J.W.3
  • 29
    • 41549139577 scopus 로고    scopus 로고
    • Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn's disease
    • Reilly MC, Gerlier L, Brabant Y, et al. Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn's disease. Clin Ther 2008;30:393-404.
    • (2008) Clin Ther , vol.30 , pp. 393-404
    • Reilly, M.C.1    Gerlier, L.2    Brabant, Y.3
  • 30
    • 0029775580 scopus 로고    scopus 로고
    • The Short Inflammatory Bowel Disease Questionnaire: A quality of life instrument for community physicians managing inflammatory bowel disease
    • CCRPT Investigators. Canadian Crohn's Relapse Prevention Trial
    • Irvine EJ, Zhou Q, Thompson AK. The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn's Relapse Prevention Trial. Am J Gastroenterol 1996;91:1571-8.
    • (1996) Am J Gastroenterol , vol.91 , pp. 1571-1578
    • Irvine, E.J.1    Zhou, Q.2    Thompson, A.K.3
  • 31
    • 0024587749 scopus 로고
    • A new measure of health status for clinical trials in inflammatory bowel disease
    • Guyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989;96:804-10.
    • (1989) Gastroenterology , vol.96 , pp. 804-810
    • Guyatt, G.1    Mitchell, A.2    Irvine, E.J.3
  • 32
    • 84880570843 scopus 로고    scopus 로고
    • Comparison of techniques for monitoring IFX bioavailability and immunogenicity in Crohn's disease
    • Steenholdt C. Comparison of techniques for monitoring IFX bioavailability and immunogenicity in Crohn's disease. Ther Drug Monit 2013;35:530-8.
    • (2013) Ther Drug Monit , vol.35 , pp. 530-538
    • Steenholdt, C.1
  • 33
    • 80054859408 scopus 로고    scopus 로고
    • Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNFα antagonists
    • Lallemand C, Kavrochorianou N, Steenholdt C, et al. Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNFα antagonists. J Immunol Methods 2011;373:229-39.
    • (2011) J Immunol Methods , vol.373 , pp. 229-239
    • Lallemand, C.1    Kavrochorianou, N.2    Steenholdt, C.3
  • 34
    • 44649187924 scopus 로고    scopus 로고
    • Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: Meta-analysis of placebo-controlled trials."
    • Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials." Clin Gastroenterol Hepatol 2008;6:644-53.
    • (2008) Clin Gastroenterol Hepatol , vol.6 , pp. 644-653
    • Peyrin-Biroulet, L.1    Deltenre, P.2    De Suray, N.3
  • 35
    • 33846592386 scopus 로고    scopus 로고
    • Hepatosplenic T cell lymphoma associated with IFX Use in young patients treated for inflammatory bowel disease
    • Mackey AC, Green L, Liang LC, et al. Hepatosplenic T cell lymphoma associated with IFX Use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;44:265-7.
    • (2007) J Pediatr Gastroenterol Nutr , vol.44 , pp. 265-267
    • Mackey, A.C.1    Green, L.2    Liang, L.C.3
  • 36
    • 72949116165 scopus 로고    scopus 로고
    • A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: A Cochrane overview
    • Singh JA, Christensen R, Wells GA, et al. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ 2009;181:787-96.
    • (2009) CMAJ , vol.181 , pp. 787-796
    • Singh, J.A.1    Christensen, R.2    Wells, G.A.3
  • 37
    • 79955844276 scopus 로고    scopus 로고
    • 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis
    • van der Heijde D, Sieper J, Maksymowych WP, et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011;70:905-8.
    • (2011) Ann Rheum Dis , vol.70 , pp. 905-908
    • Van Der Heijde, D.1    Sieper, J.2    Maksymowych, W.P.3
  • 38
    • 84870322518 scopus 로고    scopus 로고
    • Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity
    • Harigai M, Takeuchi T, Tanaka Y, et al. Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity. Mod Rheumatol 2012;22:814-22.
    • (2012) Mod Rheumatol , vol.22 , pp. 814-822
    • Harigai, M.1    Takeuchi, T.2    Tanaka, Y.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.